Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAD001 + Trastuzumab in HER2-Positive Metastatic Breast Cancer
NCT00458237Phase 2Completed
- Sponsor
- Beth Israel Deaconess Medical Center
- Start
- Apr 2007
- Primary completion
- Apr 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of everolimus in breast cancer (3 arms), sponsored by Beth Israel Deaconess Medical Center. Primary endpoint: Maximum Tolerated Dose. Started Apr 2007; status: completed.
02
Drugs
everolimus
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00458237.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00458237.